Dark

Check out our Dark Pool Levels

BLPH
BELLEROPHON THERPETCS INC
stock OTC

Inactive

Dec 18, 2024

0.0120USD-25.466%(-0.0041)7,027

Pre-market

0.00USD-100.000%(-0.02)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 10, 2022

07:00AM EST Bellerophon to Present at the H.C. Wainwright BioConnect 2022 GlobeNewswire Inc

Dec 20, 2021

10:09AM EST Mid-Morning Market Update: Markets Open Lower; Carnival Reports Downbeat Q4 Revenue Benzinga

07:25AM EST The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET). RTTNews

Dec 17, 2021

02:47PM EST Mid-Afternoon Market Update: Crude Oil Drops Over 2%; Bottomline Technologies Shares Spike Higher Benzinga

12:05PM EST Mid-Day Market Update: Dow Tumbles 500 Points; Abeona Therapeutics Shares Plummet Benzinga

10:19AM EST Mid-Morning Market Update: Markets Open Lower; Darden Restaurants Posts Upbeat Earnings Benzinga

10:09AM EST What Is Pushing Bellerophon Stock? RTTNews

08:32AM EST Bellerophon Reports Positive Top-Line Data From Phase 2 Acute Dose Escalation Study Of INOpulse For Treatment Of Pulmonary Hypertension Associated With Sarcoidosis Benzinga

08:30AM EST Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial GlobeNewswire Inc

Nov 15, 2021

11:13AM EST Bellerophon Therapeutics Q3 EPS $(0.49) Up From $(0.84) YoY Benzinga

08:30AM EST Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2021. GlobeNewswire Inc

Sep 7, 2021

08:30AM EDT Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced thatFabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021. GlobeNewswire Inc

Aug 24, 2021

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 5, 2021

08:53AM EDT Bellerophon Therapeutics Q2 EPS $(0.36) Up From $(0.51) YoY Benzinga

Jun 23, 2021

02:31PM EDT Mid-Afternoon Market Update: Patterson Companies Drops On Earnings Miss; Entera Bio Shares Gain Benzinga

12:19PM EDT Shares of Bellerophon Therapeutics Inc. (BLPH) are currently gaining nearly 27% on Wednesday morning despite no stock-related statement release from the company to drive the shares. RTTNews

12:14PM EDT Mid-Day Market Update: Crude Oil Rises Over 1%; Gemini Therapeutics Shares Slide Benzinga

10:59AM EDT Mid-Morning Market Update: Markets Rise; IHS Markit Earnings Beat Views Benzinga

May 27, 2021

08:30AM EDT Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced thatFabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021. GlobeNewswire Inc

May 26, 2021

08:34AM EDT Bellerophon Therapeutics Appoints Naseem Amin As Chairman Of Board RTTNews

08:34AM EDT Bellerophon Appoints Naseem Amin, M.D. As Chairman Of Its Board Of Directors Benzinga

08:30AM EDT Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 11, 2021

08:35AM EDT Bellerophon Therapeutics Q1 EPS $(0.58) Up From $(1.08) YoY Benzinga

08:30AM EDT Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 16, 2021

08:01AM EDT The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs Benzinga

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 8, 2021

08:14AM EDT The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

Mar 11, 2021

08:41AM EST Bellerophon Therapeutics Q4 EPS $(0.84) Up From $(0.89) YoY Benzinga

08:30AM EST Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020. GlobeNewswire Inc

Mar 2, 2021

08:30AM EST Bellerophon to Present at the H.C. Wainwright Global Life Sciences GlobeNewswire Inc

Jan 4, 2021

08:30AM EST Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021. GlobeNewswire Inc

Dec 26, 2020

09:16AM EST The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks Benzinga

Dec 1, 2020

08:34AM EST Bellerophon Says First Patient Enrolled In REBUILD Phase 3 Clinical Study Evaluating INOpulse RTTNews

08:32AM EST Bellerophon Therapeutics Reports First Patient Enrolled In Phase 3 REBUILD Study Evaluating INOpulse For Treatment Of Fibrotic Interstitial Lung Disease Benzinga

08:30AM EST Bellerophon Therapeutics Announces First Patient Enrolled in Phase GlobeNewswire Inc

Nov 23, 2020

02:35PM EST Mid-Afternoon Market Update: Dow Surges 250 Points; Bellerophon Therapeutics Shares Slide Benzinga

12:17PM EST Mid-Day Market Update: Nasdaq Edges Lower; DPW Shares Spike Higher Benzinga

10:41AM EST Mid-Morning Market Update: Markets Open Higher; AstraZeneca Covid-19 Vaccine Shows Up To 90% Efficacy In Late-Stage Trials Benzinga

08:32AM EST Bellerophon Therapeutics Puts COViNOX Study Of INOpulse For COVID-19 On Clinical Hold Benzinga

08:30AM EST Bellerophon Therapeutics Announces Results of Interim Analysis of GlobeNewswire Inc

Nov 11, 2020

08:30AM EST Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference. GlobeNewswire Inc

Nov 5, 2020

08:34AM EST Bellerophon Therapeutics Q3 EPS $(0.84) Down From $(0.06) YoY Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

08:41AM EDT Bellerophon To Present Results From Phase 2 iNO-PF Study Of INOpulse For Treatment Of Fibrotic Interstitial Lung Disease At Upcoming Scientific Conferences Benzinga

08:30AM EDT Bellerophon to Present Results from its Phase 2 iNO-PF Study of GlobeNewswire Inc

Sep 14, 2020

11:49AM EDT Insider Buys Bellerophon Therapeutics Shares Benzinga

08:30AM EDT Bellerophon to Present at Two September Investor Conferences GlobeNewswire Inc

Aug 12, 2020

09:41AM EDT Benzinga's Top Upgrades, Downgrades For August 12, 2020 Benzinga

Aug 11, 2020

08:39AM EDT Bellerophon Appoints Wassim Fares As Chief Medical Officer RTTNews

08:30AM EDT Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that it has appointed Wassim Fares, M.D., MSCR, as Chief Medical Officer. GlobeNewswire Inc

05:48AM EDT Jefferies Initiates Coverage On Bellerophon Therapeutics with Buy Rating, Announces Price Target of $19 Benzinga

Aug 5, 2020

08:30AM EDT Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2020. GlobeNewswire Inc

Jul 15, 2020

08:32AM EDT Bellerophon Therapeutics Announces Publication Of Cohort 1 Of iNO-PH Phase 2/3 Study In The CHEST Journal, Participation In Webinar To Discuss Clinical Results Benzinga

08:30AM EDT Patients Treated with INOpulse Demonstrated Improved Physical Activity Compared to Placebo GlobeNewswire Inc

Jul 13, 2020

08:39AM EDT Bellerophon Says First Patient Treated In Phase 3 Study Of INOpulse INO Therapy For COVID-19 RTTNews

08:33AM EDT Bellerophon Therapeutics Announces First Patient Treated In Phase 3 Clinical Study Of INOpulse Inhaled Nitric Oxide Therapy For COVID-19 Benzinga

08:30AM EDT Bellerophon Therapeutics Announces First Patient Treated in Phase GlobeNewswire Inc

Share